Toledo, F. B.; Milanéz-López, B.
April 1958
Angiology;Apr1958, Vol. 9 Issue 2, p88
Academic Journal
Examines the utility of thromboelastography in the study of vascular diseases. Schematic description of the thromboelastograph; Ability of thromboelastography to diagnose increases in coagulation and the difference between thrombosis and hemorrhage; Usefulness of the procedure in determining whether or not the prescribed anticoagulant is beneficial.


Related Articles

  • A Study on Ratio of Loss to Storage Modulus for the Blood Clot. Soleimani, S.; Pennati, G.; Dubini, G. // International Journal of Engineering (1025-2495);Aug2014, Vol. 27 Issue 8, p1167 

    In this study, the rheology of blood clot is measured with the help of rotational rheometer. Several shear strains (0.5, 1 and 2%) are applied with two frequencies (5 and 10 Hz) from the incipient time of clot formation and the response of the sample is measured in the form of shear stress and...

  • Fibrinolytic Compromise by Synthetic and Recombinant Thrombin Inhibitors: Implications in the Treatment of Thrombotic Disorders. Callas, Demetra D.; Iqbal, Omer; Hoppensteadt, Debra; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Spring1995, Vol. 1 Issue 2, p114 

    Site-directed synthetic and recombinant antithrombin agents are widely used to prevent reocclusion during thrombolytic therapy in acute myocardial infarction and other vascular occlusive disorders. However, minimal studies have been conducted to examine the interactions between these...

  • Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test. Gerbutavicius, Rolandas; Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra A.; Demir, Muzaffer; Khan, Erum; Bacher, Peter; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Oct2000, Vol. 6 Issue 4, p190 

    Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT). and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies...

  • Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention: How Many and How Much? Duffy, Brendan; Bhatt, Deepak L. // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p307 

    Antiplatelet agents play a major role in patients undergoing percutaneous coronary intervention (PCI). Stent thrombosis and the demand for improved clinical outcomes have driven the need for aggressive antiplatelet and anticoagulant regimens and newer, more efficacious, therapies. The benefits...

  • A MOUSE MINUS CLOTTING FACTOR GENE. Kingman, Sharon // BioWorld Today;2/11/2014, Vol. 25 Issue 28, p9 

    The article focuses on the anticoagulation therapy experiments using the antibody 3F7 developed in 2005 by Swedish, Australian and German researchers. The study showed that mice which were manipulated genetically to block the clotting factor XII were protected from the development of thrombosis....

  • Azathioprine/warfarin interaction.  // Reactions Weekly;6/7/2008, Issue 1205, p8 

    The article describes the case of 29-year-old woman with Cogan's syndrome who developed warfarin resistance following concomitant treatment with azathioprine. She was taken to an anticoagulation clinic following an incidence of thrombosis and was given enoxaparin sodium and warfarin until she...

  • Prevalence of Antiphospholipid Antibodies and Lupus Anticoagulant in Juvenile Patients with Objectively Documented Deep-Vein Thrombosis. Zanon, E.; Saracino, M. A.; Simioni, Paolo; Cogo, Alberto; Fadin, M. A.; Gavasso, S.; Girolami, Antonio // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p69 

    The prevalence of lupus anticoagulant (LA) and antiphospholipid antibodies (APA) in young patients (<45 years) with deep-vein thrombosis (DVT) is not clearly defined yet. We studied 93 consecutive patients (36 males, 57 females; aged 15 to 45) with objectively documented DVT. A control group...

  • Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. Ellis, Martin H.; Hadari, Ruth; Tchuvrero, Noa; Shapira, Shirley; Kovlenko, Irena; Kozmìakova, Mariana; Zissin, Rivka; Elis, Avishay // Clinical & Applied Thrombosis/Hemostasis;Apr2006, Vol. 12 Issue 2, p199 

    Low molecular weight heparins (LMWHs) are a rapidly growing class of anticoagulant drug. Their efficacy has been demonstrated in several clinical settings where they are rapidly becoming the anticoagulant of choice. Controlled clinical studies in patients with deep vein thrombosis, pulmonary...

  • Thrombosis during off pump LVAD placement in a patient with heparin induced thrombocytopenia using bivalirudin. Awad, Hamdy; Bryant, Richard; Malik, Obaid; Dimitrova, Galina; Sai-Sudhakar, Chittoor Bhaskar // Journal of Cardiothoracic Surgery;2013, Vol. 8 Issue 1, p1 

    Here we present our attempt at off pump HeartMate II left ventricular assist device (LVAD) implantation using the anticoagulant bivalirudin in a patient with heparin induced thrombocytopenia, which resulted in thrombosis within the LVAD device. This required that our procedure be converted to on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics